| 1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34.
|
| 2. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| 3. |
Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg, 2015, 20: 8-16.
|
| 4. |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
|
| 5. |
Zhang XP, Wang K, Li N, et al. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer, 2017, 17(1): 902.
|
| 6. |
Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg, 2016, 86(10): 816-820.
|
| 7. |
程樹群, 吳孟超, 陳漢, 等. 肝癌門靜脈癌栓分型的影像學意義. 中華普通外科雜志, 2004, 19(4): 200-201.
|
| 8. |
Chen SQ, WU MC, Chen H, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. Hepatogastroenterology, 2007, 54(74): 499-502.
|
| 9. |
Ikai I, Yamamoto Y, Yamamoto N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am, 2003, 12(1): 65-75.
|
| 10. |
Kudo M, Kitano M, Sakurai T, et al. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: The outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis, 2015, 33(6): 765-770.
|
| 11. |
Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol, 2010, 17(8): 2073-2080.
|
| 12. |
Shi J, Lai EC, Li N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci, 2011, 18(1): 74-80.
|
| 13. |
Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol, 2011, 18(2): 413-420.
|
| 14. |
Lee HS, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer, 1997, 79(11): 2087-2094.
|
| 15. |
Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol, 2012, 29(4): 2992-2997.
|
| 16. |
Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology, 2011, 258(2): 627-634.
|
| 17. |
Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol, 2009, 24(5): 806-814.
|
| 18. |
Peng ZW, Guo RP, Zhang YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer, 2012, 118(19): 4725-4736.
|
| 19. |
Zheng N, Wei X, Zhang D, et al. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore), 2016, 95(26): e3959.
|
| 20. |
Zhou Q, Wang Y, Zhou X, et al. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pac J Cancer Prev, 2011, 12(11): 2847-2850.
|
| 21. |
Xue TC, Xie XY, Zhang L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol, 2013, 13: 60.
|
| 22. |
馬良, 葉甲舟, 向邦德, 等. 不同治療方案對直徑小于 10 cm 肝細胞癌合并門靜脈癌栓患者生存率的影響. 中華肝膽外科雜志, 2013, 19(3): 165-170.
|
| 23. |
黎洪浩, 區慶嘉, 陳積圣, 等. 肝癌根治性切除術后聯合肝動脈化療栓塞和門靜脈化療對預防復發的價值. 中華腫瘤雜志, 2000, 22(1): 61-77.
|
| 24. |
Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg, 2009, 198(3): 313-318.
|
| 25. |
Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage Ⅲ A hepatocellular carcinoma. J Cancer Res Clin Oncol, 2009, 135(10): 1437-1445.
|
| 26. |
Zhang YF, Guo RP, Zou RH, et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol, 2016, 26(7): 2078-2088.
|
| 27. |
Li JQ, Zhang YQ, Zhang WZ, et al. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol, 1995, 121(6): 364-366.
|
| 28. |
Shi M, Zhang CQ, Zhang YQ, et al. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg, 2004, 28(4): 376-381.
|
| 29. |
Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after r0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol, 2016, 23(4): 1344-1351.
|
| 30. |
Li XL, Guo WX, Hong XD, et al. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. Hepatol Res, 2016, 46(11): 1088-1098.
|
| 31. |
Rim CH, Yang DS, Park YJ, et al. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol, 2012, 42(8): 721-729.
|
| 32. |
Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol, 2016, 34(5): 452-459.
|
| 33. |
廣東省抗癌協會肝癌專業委員會廣東省醫學會肝膽胰外科學分會. 肝細胞肝癌合并門靜脈癌栓多學科團隊綜合治療廣東專家共識(2015版). 中華消化外科雜志, 2015, 14(9): 694-701.
|
| 34. |
全國肝癌合并癌栓診治研究協作組. 肝細胞癌合并門靜脈癌栓多學科診治中國專家共識(2016年版). 中華醫學雜志, 2016, 96(18): 1399-1404.
|
| 35. |
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase Ⅲ trial. J Hepatol, 2012, 57(4): 821-829.
|
| 36. |
Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology, 2013, 269(2): 603-611.
|
| 37. |
Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib—a retrospective controlled study. Radiology, 2014, 272(1): 284-293.
|
| 38. |
Yang M, Yuan JQ, Bai M, et al. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep, 2014, 41(10): 6575-6582.
|
| 39. |
Zhang L, Hu P, Chen X, et al. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One, 2014, 9(6): e100305.
|
1/5
WeChat